• New Studies Move Topical Minocycline Foam for Rosacea Closer To Approval

    7 monthes ago - By Surgical Aesthetics Magazine

    Two phase 3 studies of Foamix Pharmaceuticals' FMX103 were published in the Journal of the American Academy of Dermatology. Foamix conducted FX2016-11 and FX2016-12 to support the New Drug Application submission of FMX103, which is currently under review by the U.S. Food and Drug Administration for the treatment of moderate-to-severe papulopustular rosacea in adults.
    Both studies demonstrated high statistically significant superiority of FMX103 compared with vehicle in both primary endpoints of absolute inflammatory lesion reduction and Investigator's Global Assessment treatment success at...
    Read more ...